CLIA Waiver Wave? Applications Up In FY 2014 After A Prior-Year Lull
This article was originally published in The Gray Sheet
Executive Summary
The volume of applications for diagnostic test waivers under the Clinical Laboratory Improvement Amendments increased fivefold in FY 2014, but the total numbers are small, and the change may simply reflect routine year-to-year variation.
You may also be interested in...
Cepheid Flu Test Wins First CLIA Waiver For PCR Panel
FDA granted both a 510(k) clearance and a waiver for point-of-care use to Cepheid’s Xpert Flu +RSV Express test – the first molecular-based, polymerase chain-reaction panel diagnostic to win a CLIA waiver.
Coming Together On CLIA Waivers? Industry Hopes To Recruit Patients, Providers To Push Reform
Diagnostic firms formed the Coalition for CLIA Waiver Reform last month with the goal of enlisting patients, labs and physicians in the fight to turn back what they say are unreasonable FDA standards for a test to gain access to the broader market of “waived” labs.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.